The results of the selected study are necessary to confirm that supplementation with 200 µg of selenium safely and effectively reduces the risk of prostate cancer in healthy men.
Most research on selenium supplements focuses on the prevention of prostate cancer.
It is currently unclear whether OTC selenium preparations should be used to treat prostate cancer.
Animal and population studies have shown that selenium supplementation can reduce the risk of cancer.
The results of the Food Prevention Cancer (NPC) study showed that selenium supplements do not affect the risk of skin cancer, but significantly reduce the incidence of lung, colorectal and prostate cancer.
However, studies on the effects of selenium in the blood on the risk of prostate cancer have shown mixed results.
Studies on the effects of selenium in the blood on the risk of developing prostate cancer have shown mixed results.
A study in which patients were followed for up to 10 years showed that men with higher blood selenium levels have a lower risk of prostate cancer.
Another study found that patients with prostate cancer had lower levels of selenium in whole blood than healthy men.
However, a 2009 study on prostate cancer patients showed that men with higher blood selenium levels were more likely to be diagnosed with aggressive prostate cancer.
One study found no relationship between dietopane lycopene and tomatoes and the risk of prostate cancer in the general population.
However, in men with a history of disease, higher levels of lycopene in the diet were associated with a lower risk of prostate cancer.
Another study in the same group of men found no difference in blood lycopene levels between healthy men and men who developed prostate cancer.
Mouse strains designed to develop prostate cancer that behaves like human cancer received lycopene granules or tomato paste.
Mice on a lycopene ball diet showed a greater decrease in prostate cancer rates than mice on a tomato paste diet.
The combination of lycopene and dried tomato substance (FruHis) slowed the growth of prostate cancer cells in rats more than lycopene or FruHis alone.
A study in mice injected with human prostate cancer cells showed that mice treated with lycopene or beta-carotene preparations showed less tumor growth.
Lycopene-treated prostate cancer cells had changes in the cell division cycle, resulting in less cancer cell growth.
Treatment of prostate cancer cells with lycopene may change the way androgen (the male hormone) is taken up and used in cells and may reduce the growth of cancer cells.
The combination of lycopene with standard cancer medicines can help stop the spread of different types of prostate cancer cells than with medicines alone.
Laboratory and preclinical studies have shown that catechins slow down the spread of prostate cancer, blocking the stimulating effect of androgens (male hormones such as testosterone), and can block the protein involved in the growth of prostate cancer.
Catechins increase the susceptibility of prostate cancer cells to radiation and hormone therapy.
Drinking coffee is associated with a lower risk of recurrence and progression of prostate cancer.
After 24 weeks, mice given normal water developed prostate cancer, while mice given water with green tea catechins showed only intraepithelial (pin) prostate cancer.
The results suggest that green tea catechins may delay the development of prostate cancer by blocking the protein involved in cancer growth.
Mice that received EGCG treatment had lower levels of proteins needed for androgen activity than mice treated with placebo.
The results suggest that EGCG blocks androgen stimulating effects on cancer cells in a way that may be useful in prostate cancer that can be treated with hormone therapy, as well as in prostate cancer that does not respond to hormone therapy.
Mice strains cultured to develop prostate cancer that acts like human cancer were on a genistein diet or control diet.
Compared to mice on the control diet, mice receiving the genistein diet had less prostate cancer cell growth and less growth stimulating protein.
A study in mice implanted with advanced prostate cancer showed that those who received genistein in peanut oil daily developed more tumors in other parts of the body than mice that received peanut oil without genistein.
Few studies, including the study of prostate cancer, have reported the impact of MCP on animal cancer models.
Rats injected with prostate cancer cells and treated with MCP showed less spread of lung cancer, but had no effect on tumor growth at the primary site of the cancer.
Some studies in patients with prostate cancer suggest that MCP may have some benefits in the fight against cancer.
Although the exact role of nutrition in prostate cancer is unclear, researchers have investigated several factors and are still looking for more specific links between nutrition and prostate cancer.
Many foods that are thought to reduce risk and improve survival after prostate cancer are products of plant origin.
Some of the many foods and nutrients associated with prostate cancer risk and survival are listed below.
Zinc is advertised as a method of improving the immune system for prostate health.
Patients with chronic prostatitis usually have low levels of zinc in the prostate or sperm.
In fact, high doses of extra zinc have been found to cause abnormal changes in the immune system, leading to increased urinary tract infections, an enlarged prostate, and an increased risk of aggressive prostate cancer.